Free PhysChem Calculator

Draw a molecule or paste SMILES to instantly calculate MW, LogP, TPSA, Fsp3, ESOL solubility, QED score, Lipinski Ro5 and Veber criteria. Structural alerts are highlighted directly on the molecule structure. No signup required.

What is Lipinski's Rule of Five?

In 1997, Lipinski and colleagues at Pfizer analysed compounds that had reached Phase II clinical trials and identified property ranges correlated with good oral absorption. The Rule of Five flags poor absorption when:

> 500 Da

Molecular weight

> 5

LogP

Lipophilicity

> 5

Hydrogen-bond donors

NH and OH groups

> 10

Hydrogen-bond acceptors

N and O atoms

It is called the "Rule of Five" because every threshold is a multiple of five: a useful reminder that these are round-number heuristics, not precise cutoffs. Compounds violating two or more parameters are statistically less likely to succeed as oral drugs, but these are guidelines for probability, not laws of nature.

Veber's Criteria: flexibility and polarity

In 2002, Veber and colleagues at GlaxoSmithKline analysed over 1,100 drug candidates tested for oral bioavailability in rats. They found that molecular flexibility and polarity were strong predictors of oral absorption, independent of molecular weight:

≤ 140

Topological polar surface area

TPSA, Ų

≤ 10

Rotatable bonds

≤ 12

Total hydrogen-bond count

HBD + HBA

TPSA measures the surface area contributed by polar atoms (nitrogen, oxygen, and their attached hydrogens). Higher polarity reduces passive membrane permeability. Rotatable bonds measure molecular flexibility: a more flexible molecule must pay a larger conformational entropy cost to adopt the geometry needed for membrane permeation, which correlates with reduced oral bioavailability. The total H-bond count captures overall polarity in a complementary way to TPSA.

This calculator checks all three Veber criteria alongside Lipinski's Rule of Five and displays all seven properties in a radar chart for easy visual comparison.

What is QED?

QED (Quantitative Estimate of Drug-likeness) was introduced by Bickerton et al. in Nature Chemistry (2012). Instead of applying binary pass/fail thresholds, QED maps each of eight molecular properties through a desirability function derived from the distributions observed in approved oral drugs, then combines them into a single score between 0 and 1.

The eight QED properties

MW

Molecular weight

LogP

Lipophilicity

HBD

H-bond donors

HBA

H-bond acceptors

PSA

Polar surface area

RotB

Rotatable bonds

Arom

Aromatic rings

Alerts

Structural alerts

Structural alerts check against 116 SMARTS patterns flagging reactive or toxic substructures. Matched atoms are colour-coded and highlighted directly on the molecule structure so you can see exactly which part of the molecule triggered each alert.

QED Score Interpretation

< 0.4
0.4 to 0.65
≥ 0.65
UnfavourableModerateFavourable

Because QED uses weighted desirability functions rather than hard cutoffs, it captures a more nuanced picture of drug-likeness than any single rule set.

Guidelines, not rules: the "beyond Ro5" space

The Ro5 predicts the likelihood of adequate absorption, not overall clinical success. Many approved drugs violate one or more thresholds:

Atorvastatin (MW 559 Da) exceeds the MW threshold yet is one of the most commercially successful drugs in history.

Erythromycin (MW 734 Da, ~30% bioavailability), rifampicin (MW 823 Da, ~90% bioavailability), and cyclosporine A (MW 1203 Da, 20-60% bioavailability) have been successful oral medicines for decades.

More recently, HCV protease inhibitors like glecaprevir (MW 838 Da) and cancer drugs like venetoclax (MW 868 Da) achieve effective oral exposure.

27%

of oral drugs approved since 2000 exceed 500 Da. Of the four Lipinski parameters, LogP > 5 is arguably the most consequential violation. High lipophilicity correlates with increased attrition across all stages of development.

Curious about the science behind these drugs?

Explore how atorvastatin, venetoclax, and over 50 other famous molecules were discovered, optimised, and brought to patients. Real science, real stories.

Molecule Stories